Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer: A southwest oncology group study

D. D. Von Hoff, S. Green, E. A. Surwit, E. V. Hannigan, D. S. Alberts

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Twenty evaluable patients with advanced cervical cancer refractory to one prior chemotherapy regimen were treated with a 5-day schedule of fludarabine phosphate. No responses were noted. The major toxicities were anemia and leukopenia. Based on this study, fludarabine phosphate does not appear to be an active agent for patients with chemotherapy refractory cervical cancer.

Original languageEnglish (US)
Pages (from-to)433-435
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume13
Issue number5
DOIs
StatePublished - Jan 1 1990
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of fludarabine phosphate (NSC 312887) in patients with advanced cervical cancer: A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this